HOMOVANILLIC ACID AND 5‐HYDROXYINDOLEACETIC ACID IN THE CEREBROSPINAL FLUID OF PATIENTS WITH SENILE DEMENTIA, PRESENILE DEMENTIA AND PARKINSONISM

No abstract is available for this paper.

• Publication year

  1969

• Venue

  Journal of Neurochemistry

• Publication date

  1969-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/J.1471-4159.1969.TB05984.XPMID 5808100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 5-hydroxyindoleacetic acid in ventricular cerebrospinal fluid and brain of normal and hydrocephalic dogs after administration of 5-hydroxytryptophan. II.

  2009cited by this paper
• 5-hydroxyindoleacetic acid in cerebrospinal fluid after administration of 5-hydroxytryptophan I.

  2009cited by this paper
• The Investigation of Homovanillic Acid in the Human Brain and its Correlation to Senile Dementia

  1969cited by this paper
• Concentrations of 5-Hydroxyindole-acetic Acid and Homovanillic Acid in the Cerebrospinal Fluid after Treatment with Probenecid in Patients with Parkinson's Disease

  1968cited by this paper
• The effect of probenecid on the elimination from CSF of intraventricularly injected 5‐hydroxyindoleacetic acid in normal and hydrocephalic dogs

  1968cited by this paper
• Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease.

  1968cited by this paper
• CSF 5HIAA: Effects of probenecid and parachlorophenylalanine

  1968cited by this paper
• Gegenwärtiger Stand der biochemisch-pharmakologischen Erforschung des extrapyramidalmotorischen Systems

  1968cited by this paper
• The effect of probenecid on the elimination from CSF of intraventricularly injected 5-hydroxyindoleacetic acid in normal and hydrocephalic dogs

  1968cited by this paper
• 5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome.

  1967cited by this paper
• Cholinergic-anticholinergic antagonism in parkinsonism.

  1967cited by this paper
• Concentrations of 5-hydroxyindolylacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with probenecid.

  1966cited by this paper
• Reciprocal Effects on α- and γ-Motoneurones of Drugs Influencing Monoaminergic and Gholinergic Transmission

  1966cited by this paper
• Reciprocal effects on alpha- and gamma-motoneurones of drugs influencing monoaminergic and cholinergic transmission.

  1966cited by this paper
• On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method.

  1963cited by this paper
• 5-Hydroxyindoles in Human Cerebrospinal Fluids

  1960cited by this paper

• Targeting the serotonergic system in the treatment of neurodegenerative diseases—emerging therapies and unmet challenges

  2025cites this paper
• Dopamine System Dysfunction in Alzheimer's Disease

  2025cites this paper
• A Simple and Efficient Turn‐Off Fluorescence Sensor for the Nanomolar Detection of Homovanillic Acid Using Protein Mediated Blue Emitting Nickel Nanoclusters

  2021cites this paper
• New frontiers in Alzheimer's disease diagnostic: Monoamines and their derivatives in biological fluids.

  2021cites this paper
• An Integrative Literature Review on the Nomenclature and Definition of Dementia at a Young Age

  2021cites this paper
• Conventional and novel pharmacological approaches to treat dopamine-related disorders. Focus on Parkinson's disease and schizophrenia.

  2020cites this paper
• Gottfries’ Cognitive Scale for Staff Proxy Rating of Cognitive Function Among Nursing Home Residents

  2019cites this paper
• Mechanism-based pharmacokinetics-pharmacodynamics studies of harmine and harmaline on neurotransmitters regulatory effects in healthy rats: Challenge on monoamine oxidase and acetylcholinesterase inhibition.

  2019cites this paper
• Alzheimer Disease and Selected Risk Factors Disrupt a Co-regulation of Monoamine Oxidase-A/B in the Hippocampus, but Not in the Cortex

  2018cites this paper
• Depression in Parkinson's Disease is Associated with a Serotoninergic System Change Secondary to Neuroinflammation

  2016cites this paper
• Fluid Biomarkers and Diagnostics

  2016cites this paper
• Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases.

  2016cites this paper
• Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions

  2014cites this paper
• Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

  2014cites this paper
• CSF in Alzheimer's disease.

  2014cites this paper
• Levodopa: A Review of its Pharmacological Properties and Therapeutic Uses with Particular Reference to Parkinsonism

  2012cites this paper
• Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: More to Come?

  2012cites this paper
• The serotonergic system in Parkinson's disease.

  2011cites this paper
• Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus?

  2011cites this paper
• Reliability and validity of the Norwegian version of the Brief Agitation Rating Scale (BARS) in dementia

  2011cites this paper
• Agitation in Patients with Dementia - Challenges in Diagnosis and Treatment

  2010cites this paper
• Tryptophan malabsorption in levodopa-treated parkinsonian patients. Effect of tryptophan on mental disturbances.

  2009cites this paper
• Chapter 14. Monoamine Metabolites in the Cerebrospinal Fluid: Indicators of the Biochemical Status of Monoaminergic Neurons in the Central Nervous System

  2008cites this paper
• Monoamine neurons in aging and Alzheimer's disease

  2005cites this paper
• Increased CSF HVA response to arecoline challenge in Alzheimer's disease

  2005cites this paper
• Monoamine acid metabolites in ventricular CSF of patients with brain tumours

  2005cites this paper
• Serotoninergic impairment and aggressive behavior in Alzheimer's disease.

  2005cites this paper
• The mechanism of perturbation in monoamine metabolism by L-DOPA therapy: in vivo and in vitro studies

  2005cites this paper
• Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus

  2004cites this paper
• Separationand Identificationof Neutral and Acidic

  2004cites this paper
• The effects of probenecid on cyclic adenosine 3′, 5′-monophosphate levels in cerebrospinal fluid and on brain phosphodiesterase activity in the rat

  2004cites this paper
• Dopamine (DA) and serotonin metabolic levels in the cerebrospinal fluid (CSF) in Alzheimer's presenile dementia under basic conditions and after stimulation with cerebral cortex phospholipids (BC-PL)

  2004cites this paper
• Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease.

  2001cites this paper
• Concentration of specific biogenic amines in ventricular CSF of type A and B Parkinson's disease patients on Sinemet

  2001cites this paper
• Serotonergic Decompensation in the Akinetic Expression of Parkinson's Disease

  2000cites this paper
• Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia and agitation.

  1998cites this paper
• Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type.

  1996cites this paper
• Reversal of an acute parkinsonian syndrome associated with multiple sclerosis by application of weak electromagnetic fields.

  1996cites this paper
• Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach.

  1996cites this paper
• Capillary zone electrophoretic determination of 5-hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid from patients with neuropsychiatric disorders

  1996cites this paper
• Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion.

  1995cites this paper
• Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease.

  1993cites this paper
• Monoamliines in tieBrainCerebrospinal Fluid of Facial Pain Patents

  1992cites this paper
• Neurochemical Changes with Aging: Predisposition toward Age-Related Mental Disorders

  1992cites this paper
• Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls

  1992cites this paper
• Monoamines in the brain cerebrospinal fluid of facial pain patients.

  1992cites this paper
• Serotonergic dysfunction in depression associated with Parkinson's disease

  1992cites this paper
• Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease.

  1992cites this paper
• Concentration of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type

  1992influential citation
• Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl

  1991cites this paper
• Serotoninergic approach: why serotoninergic substitution? Clinical experience with 5-HT uptake inhibitors

  1991cites this paper
• Biological Markers in Alzheimer's Disease

  1991cites this paper
• Brain metabolism in Alzheimer's dementia: studies of 11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects.

  1991cites this paper
• Cerebrospinal Fluid Markers of Alzheimer's Disease

  1991cites this paper
• Development of Psychogeriatric Medicine in Sweden

  1990cites this paper
• Relationship between abnormal brainstem auditory-evoked potentials and subnormal CSF levels of HVA and 5-HIAA in first-episode schizophrenic patients.

  1990cites this paper
• Acetylcholinesterase activities and monoamine metabolite levels in the cerebrospinal fluid of patients with Alzheimer's disease.

  1990cites this paper
• Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.

  1990cites this paper
• Neurotransmitter and Dementia

  1990cites this paper
• Effects of shosaikoto, an oriental herbal medicinal mixture, on age-induced amnesia in rats.

  1990cites this paper
• Concentration gradients for HVA, 5-HIAA, ascorbic acid, and uric acid in cerebrospinal fluid.

  1990cites this paper
• Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia.

  1990cites this paper
• Diagnosis and Treatment of Senile Dementia

  1989cites this paper
• Effect of L‐dopa on dementia‐related rigidity *

  1989cites this paper
• Biogenic amines and their metabolites in body fluids of normal, psychiatric and neurological subjects.

  1989cites this paper
• Diagnosis and Treatment of Senile Dementia: Early Diagnosis and Differential Diagnosis

  1989cites this paper
• CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: its relationship to severity of dementia and monoamine metabolites.

  1989influential citation
• Increased response of serum prolactin to metoclopramide in senile dementia of Alzheimer type

  1989cites this paper
• Integrity‐promoting care of demented nursing home patients: Psychological and biochemical changes

  1989cites this paper
• Olfaction and Psychiatry

  1989cites this paper
• Biological markers in dementia

  1988cites this paper
• CSF monoamine metabolites in dementia of the Alzheimer type and controls: Evidence for lower levels of homovanillic acid and 5‐hydroxyindoleacetic acid in patients

  1988cites this paper
• Decreased densities of dopamine D1 receptors in the putamen and hippocampus in senile dementia of the Alzheimer type.

  1988cites this paper
• Effects of environmental stimulation on biochemical and psychological variables in dementia

  1988cites this paper
• Serotonergic mechanisms in levodopa-induced "on-off" and sleep disorders in Parkinson's disease.

  1988cites this paper
• Unaltered platelet [3H]-imipramine binding in dementia of the Alzheimer type.

  1988cites this paper
• Neurochemical aspects of Alzheimer's disease: Involvement of membrane phospholipids

  1988cites this paper
• Neurochemical specificity of learning: dopamine and motor learning.

  1987cites this paper
• Neuropsychological test performance and CSF levels of monoamine metabolites in healthy volunteers and patients with Alzheimer's dementia

  1987cites this paper
• Serotonin, Alzheimer’s Disease and Learning and Memory in Animals

  1987cites this paper
• Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients

  1987cites this paper
• Neuere pharmakologische Modelle und Forschungsergebnisse in der Therapie der degenerativ und/oder vaskulär bedingten hirnorganischen Psychosyndrome bzw. Demenzen im mittleren und höheren Lebensalter

  1986cites this paper
• Serotonin Neurones and Receptors in Alzheimer’s Disease

  1986cites this paper
• Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease.

  1986cites this paper
• Neuropeptides and dementia.

  1986cites this paper
• Die senile Demenz vom Alzheimer Typ und Neurotransmission*

  1986cites this paper
• Cholinergic dysfunction in Alzheimer disease: cause or effect?

  1986cites this paper
• Laterality and neurochemical findings in Parkinson's disease.

  1986cites this paper
• CSF neurotransmitter markers in Alzheimer's disease.

  1986cites this paper
• Alzheimer's disease and serotonin: a review.

  1986cites this paper
• Neurotransmitter Systems in Alzheimer’s Disease

  1986cites this paper
• Neuropeptides in Alzheimer's disease: a review and morphological results.

  1986cites this paper
• Cerebrospinal fluid biopterin is decreased in Alzheimer's disease.

  1986cites this paper
• Monoamine activity correlates with psychometric deficits in Korsakoff's disease.

  1985cites this paper
• Nucleus raphe dorsalis in Alzheimer's disease: Neurofibrillary tangles and loss of large neurons

  1985cites this paper
• Transmitter deficits in Alzheimer's disease.

  1985cites this paper
• CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.

  1985cites this paper
• Neurotransmitters in the brains of patients with dementia disorders.

  1985cites this paper
• VASCULAR DISEASE, SENILITY, AND DEMENTIA

  1985cites this paper
• Biochemistry of Senile Dementia

  1985cites this paper